ResMed Inc. (RMD)

ResMed's stock has been influenced by several events in the past six months. Strong earnings reports for Q2 and Q3 of fiscal year 2025 showed revenue and EPS growth. The acquisition of VirtuOx contributed to its digital health strategy. Analyst sentiment improved, with RBC Capital upgrading the stock and raising its price target. Market concerns about GLP-1 drugs have periodically affected performance, but analysts believe ResMed's leadership will withstand this. Insider selling, including by the CEO, has been scrutinized. The stock reached a 52-week high, and RMD shares have outperformed the Health Care Select Sector SPDR Fund over the past three months. The company also executed a stock buyback.

Demand for ResMed's products and services is generally stable and consistent, characteristic of the healthcare industry. The stock has historically shown positive performance in July. The company's growth is driven by strong underlying demand for sleep apnea and respiratory care solutions.

ResMed Inc. is a global medical device company that develops, manufactures, and distributes medical equipment and cloud-based software for respiratory disorders like sleep apnea and COPD. Their products include airflow generators (CPAP, VPAP, APAP), masks, and accessories, along with SaaS solutions like AirView and myAir for remote monitoring and data-driven therapy adjustments.

ResMed operates in over 140 countries with manufacturing facilities in Australia, Singapore, France, and the United States. The Americas account for approximately two-thirds of its revenue, with Europe, Asia, and other markets also contributing substantially.

ResMed maintains a strong brand reputation as a global leader in sleep apnea devices and connected care solutions. Customer satisfaction is high due to device reliability, comfort, and digital support tools. Strategic acquisitions, product innovation and launches, strong financial performance, and a unified brand unveiling have positively affected ResMed's reputation. Potential threats include regulatory risk, supply chain disruptions, the return of competitors, and patent litigation.

ResMed Inc. has significant institutional ownership, with over 50% and up to 75% of shares held by institutional investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Company insiders hold some shares, valued at approximately US$655 million as of September 2021, while the general public holds a 24-25% ownership stake.